Pfizer
Chad MacGregor, MD, currently serves as the Medical Director at Pfizer, focusing on Rare Cardiology since July 2019, where responsibilities include team management, budget oversight, and leading field medical engagement strategies. Previously, Chad held roles at UCB, managing the MSL team in Immunology and serving as National Training Lead. Chad's career began at Bristol-Myers Squibb, where leadership spanned multiple roles in Medical Science Liaison and management. Academic credentials include an MD from the University of Arizona and a B.S. in Chemistry from Arizona State University. Notable achievements include the 2023 Monarch Award for innovation in medical omnichannel approaches and a series of Bravo Recognitions.
This person is not in any offices
Pfizer
606 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.